

Study #1: Exenatide Weekly Injection as an Adjunctive Treatment in Patients with Schizophrenia

Researchers at the **Psychotic Disorders Research Program** in the department of Psychiatry at **UMass Medical School** in Worcester, MA are looking for volunteers for a study involving individuals with a diagnosis of schizophrenia or schizoaffective disorder.

The goal of this study is to determine if weekly injections of exenatide can improve symptoms of schizophrenia. Some recent studies suggest that exenatide can reduce inflammation, which may protect the brain and improve memory and thinking in individuals with schizophrenia or schizoaffective disorder.

What the Study Involves:

- Visits with the research staff every week
- Answering questions about symptoms of schizophrenia, memory and thinking
- Half the people will receive exenatide, while the other half will receive a “placebo”
- Undergoing two MRIs (brain scans), one at the beginning and one at the end of the study
- The study will last for 24 weeks (6 months)

We are looking for people who:

- Are ages 18-65
- Have schizophrenia or schizoaffective disorder
- Currently take medications for schizophrenia

People in the study will be paid at each meeting for their time and expenses.
All information is kept private.

This study is funded by Stanley Medical Research Institute.

If you are interested and would like more information, please contact Radhika Natarajan at 508-856-8323 or via e-mail at Radhika.Natarajan@umassmed.edu.

Docket # H-00004119

Study #2: A Research Study on Treatment of Marijuana Use and Schizophrenia

Researchers at the **Psychotic Disorders Research Program** in the department of Psychiatry at **UMass Medical School** in Worcester, MA are looking for volunteers for a NIH-funded study involving schizophrenia and marijuana use.

We are studying whether an FDA-approved drug, clozapine, can reduce marijuana use in individuals who suffer from schizophrenia and ongoing marijuana use.

The study last about 14 weeks and involves:

- Weekly meetings with the research staff
- Answering questions about substance use and current symptoms
- Half the people in the study will get a medicine called “clozapine” and the other half will get a medicine called “risperidone”. People in the study will not know which type of pill they are getting.

We are looking for people who:

- Have been told they have schizophrenia
- Are willing to take medicine for schizophrenia
- Use marijuana regularly
- Are ages 18-55

People in the study will be compensated for their time.
All information is kept private.

If you are interested and would like more information, please contact Radhika Natarajan at 508-856-8323 or via e-mail at Radhika.Natarajan@umassmed.edu.

Docket # H-00001171

Study #3: Schizophrenia and Alcohol Study

Researchers at the **Psychotic Disorders Research Program** in the department of Psychiatry at **UMass Medical School** in Worcester, MA are looking for volunteers for a study involving schizophrenia and alcohol use.

The purpose of the study is to evaluate the safety and effectiveness of an investigational medication in treating schizophrenia in individuals ages 18 to 65 years old who use alcohol.

Each patient who qualifies will receive...

- Investigational medication
- Study-related medical exams
- Laboratory tests at no cost

Who can be in the study:

- Men and women 18 to 65 years old
- Have had a recurrence of schizophrenia symptoms within the last 6 months
- Have experienced at least 10 drinking days in the last month

Compensation for time and travel may be available.

This study is funded by Alkermes, Inc.

If you are interested and would like more information, please contact Radhika Natarajan at 508-856-8323 or via e-mail at Radhika.Natarajan@umassmed.edu.

Docket # H-00005852

Study #4: Tardive Dyskinesia Study

Researchers at the **Psychotic Disorders Research Program** in the department of Psychiatry at **UMass Medical School** in Worcester, MA are looking for volunteers for a study involving tardive dyskinesia and schizophrenia.

We invite those who are experiencing involuntary movements in their face or other parts of their body – and suffer from schizophrenia, schizoaffective disorder – to see if they may qualify for the Kinect 3 Study. The purpose of this clinical research study is to evaluate the effectiveness, safety, and tolerability of an investigational oral medication for tardive dyskinesia.

Those who qualify will receive:

- Study medication
- Study-related medical exams
- Lab tests at no charge

Key Inclusion and Exclusion Criteria:

In order to participate in the study, individuals must be evaluated by a study doctor and meet certain criteria including, but not limited to:

- Be male or female aged 18 to 85 years.
- Have clinical diagnosis of schizophrenia or schizoaffective disorder
- Have a clinical diagnosis of Tardive Dyskinesia (TD)

Compensation for time and travel may be available.

This study is funded by Neurocrine Biosciences, Inc.

If you are interested and would like more information, please contact Radhika Natarajan at 508-856-8323 or via e-mail at Radhika.Natarajan@umassmed.edu.

Docket # H-00006334